Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/222244
Title: Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party
Author: Gagelmann, Nico
De Witte, Moniek
Peczynski, Christophe
Boreland, William
E. C. Broers, Annoek
Jost, Edgar
Kulagin, Alexander
Esquirol, Albert
Sica, Simona
Kuball, Jürgen
Errico, Gerardo
Bethge, Wolfgang
Maertens, Johan
Stölzel, Friedrich
Forcade, Edouard
Collin, Matthew
Parma, Matteo
Choi, Goda
Kröger, Nicolaus
Chiara Di Chio, Maria
Chiara Finazzi, Maria
López Corral, Lucia
Rifón, Jose
Mussetti, Alberto
Bloor, Adrian
Ladetto, Marco
Schoemans, Hélène
Penack, Olaf
Moiseev, Ivan
Peric, Zinaida
Issue Date: 4-Jun-2025
Publisher: Springer Science and Business Media LLC
Abstract: Pure red cell aplasia (PRCA) is a relevant complication after ABO-mismatched allogeneic hematopoietic cell transplantation (HCT). No standard treatment exists, and practice is heterogenous. In this study, we took advantage of an international collaboration to describe characteristics and outcomes of patients receiving daratumumab for PRCA following first allogeneic HCT. We identified 45 patients meeting these criteria (median patient age, 56 years). The median time from HCT to PRCA was 55 days (IQR, 36-116) and all patients were transfusion-dependent at time of daratumumab start. Daratumumab was first-line treatment in 16 patients (36%), most patients (67%) received daratumumab intravenously, and median time from PRCA diagnosis and daratumumab start was 88 days (IQR, 59-219). Incidence of transfusion independence was 69% (95% confidence interval [CI], 52-80%) at 6 months and 80% (95% CI, 62-90%) at 12 months. Incidences of hemoglobin and reticulocyte recoveries were respectively 56 and 78% at 6 months and 65 and 83% at 12 months. Survival at 12 months was 81%, and of 8 deaths, 7 were GVHD- or infection-related. One death was associated with hemolytic anemia. This is the first international and largest study on the use of daratumumab for PRCA after allogeneic HCT, showing high response rates superior to that reported for other treatments. Seven incidents of severe adverse events (mostly infections) underscore the need for close monitoring, proactive management, and comparative studies to determine the role for daratumumab for PRCA. Last, based on these data and a comprehensive literature review, we provide practical consideration for modern PRCA treatment.
Note: Reproducció del document publicat a: https://doi.org/10.1038/s41408-025-01315-8
It is part of: Blood Cancer Journal, 2025, vol. 15, issue. 1
URI: https://hdl.handle.net/2445/222244
Related resource: https://doi.org/10.1038/s41408-025-01315-8
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
s41408-025-01315-8.pdf776.66 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.